Helix BioPharma Corp. announced voting results from its Annual General and Special Meeting held on January 30, 2026, with shareholders demonstrating overwhelming support for all proposed resolutions. A total of 61,885,815 common shares were voted at the meeting, representing 81.03% of the company's total issued and outstanding shares, indicating strong shareholder engagement in the clinical-stage oncology company's governance.
The importance of these voting results lies in the clear mandate given to Helix's leadership team as the company advances its oncology pipeline. Shareholders re-elected all four director nominees with near-unanimous approval, with each director receiving 99.99% of votes in favor. The re-elected directors include Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube, who will continue guiding the company's strategic direction for the coming year.
Shareholders also approved the appointment of Clearhouse LLP as auditor with 99.99% support and authorized a significant amendment to the company's articles. The approved amendment allows for a potential share consolidation of up to five pre-consolidation common shares for one post-consolidation common share, with the board retaining discretion to determine the final ratio. This consolidation authority provides management with flexibility to optimize the company's capital structure as it advances its clinical programs.
The implications of these voting results extend beyond routine corporate governance. For investors and the broader oncology treatment landscape, the strong shareholder support signals confidence in Helix's leadership during a critical development phase for its pipeline. The company's lead candidate, L-DOS47, has completed Phase Ib studies in non-small cell lung cancer and represents a novel approach to treating CEACAM6-expressing solid tumors. The shareholder mandate comes as Helix continues developing what it describes as "first- and best-in-class oncology medicines" through its proprietary bio-conjugate technology platform.
A complete report on all meeting resolutions will be filed on SEDAR+ at https://www.sedarplus.com, providing transparency to current and potential investors. The voting outcomes suggest shareholders support the company's strategic direction as it works toward making "today's hard-to-treat cancers vincible" through innovative therapies. For the oncology industry, continued progress by companies like Helix BioPharma could potentially expand treatment options for patients with difficult-to-treat cancers, though the company notes numerous risks and uncertainties in its forward-looking statements.
The company's website at https://www.helixbiopharma.com/ provides additional information about its research and development activities. The shareholder approval of all agenda items, particularly the share consolidation authorization, provides management with tools to potentially enhance shareholder value as the company advances its clinical programs. These governance decisions occur within the context of the competitive oncology therapeutics market, where successful development of novel treatments requires both scientific innovation and strong corporate stewardship.
